Alexandros Makriyannis

This inventor holds 57 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 2 EPO patents, primarily in Cannabinoid Compounds (CPC class C07D). Top assignees: University of Connecticut, Northeastern University, Makscientific, LLC. Active years: 1995-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alexandros Makriyannis. Retrieved from https://idiyas.com/inventor/alexandros-makriyannis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 57 (Patent Applications = 14)

% Patents Active = 77.2

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 2.8

ph-index = 13

Forward Citations = 513(Granted Patents)

Forward Citations (Not Self Cited) = 253(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Willimantic, CT (US) (2000)
Ashford, CT (US) (1995 - 2003)
Mystic, CT (US) (2005 - 2010)
Boston, MA (US) (2006 - 2018)
Watertown, MA (US) (2005 - 2024)

Company Filing History:

37 out of 784

University of Connecticut

patents

12 out of 686

Northeastern University

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

5. 1 out of 2

Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.a.

patents

where one patent can have more than one assignee

Years Active: 1995-2024

Loading Chart...

Areas of Expertise:

Cannabinergic Compounds

FAAH Inhibitors

Receptor Modulation

Cannabinoid Receptors

N-acylethanolamine

Pyrazole Derivatives

Cannabimimetic Ligands

Heteropyrrole Analogs

Bicyclic Cannabinoids

Therapeutic Applications

CB1 Antagonists

Peripheral CB2 Selective Ligands

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054480 - Compounds for treating cannabinoid toxicity and acute cannabinoid overdose (2024-08-06),

2. 11964956 - Cannabinergic compounds and uses thereof (2024-04-23),

3. 11939325 - Process for making biologically active compounds and intermediates thereof (2024-03-26),

4. 11746113 - Labelled cannabinergic ligands and related analogs (2023-09-05),

5. 11214578 - Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof (2022-01-04),

6. 10968206 - Cannabinergic nitrate esters and related analogs (2021-04-06),

7. 10882838 - Cannabinergic compounds and uses thereof (2021-01-05),

8. 10689357 - N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof (2020-06-23),

9. 10662159 - ABHD6 and dual ABHD6/MGL inhibitors and their uses (2020-05-26),

10. 10640494 - N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof (2020-05-05),

11. 10570146 - Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof (2020-02-25),

12. 10221164 - Cannabinergic nitrate esters and related analogs (2019-03-05),

13. 10053444 - Cannabinergic nitrate esters and related analogs (2018-08-21),

14. 9963444 - N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof (2018-05-08),

15. 9580400 - Cannabinergic nitrate esters and related analogs (2017-02-28),

Title: The Innovative Journey of Alexandros Makriyannis

Introduction: Alexandros Makriyannis, a pioneering inventor based in Watertown, MA (US), has made significant contributions to the field of pharmaceuticals and drug discovery.

Latest Patents: Makriyannis holds several patents in the area of medicinal chemistry and pharmacology, focusing on novel compounds for the treatment of various diseases such as cancer, neurological disorders, and chronic pain.

Career Highlights: With a distinguished career spanning over several decades, Makriyannis has served as a professor at Northeastern University and the Director of the Center for Drug Discovery. He has been instrumental in leading groundbreaking research projects that have led to the development of innovative drugs and therapies.

Collaborations: Throughout his career, Makriyannis has collaborated with leading pharmaceutical companies, research institutions, and fellow inventors to advance the field of drug discovery. His collaborative efforts have resulted in the successful translation of research findings into practical applications for patient care.

Conclusion: Alexandros Makriyannis continues to be a driving force in the world of pharmaceutical innovation, with his groundbreaking work paving the way for the development of new and improved treatments for a wide range of medical conditions. His dedication to scientific excellence and commitment to improving global health make him a true visionary in the field of drug discovery.

Profile summary based on public USPTO records.